跳至主要内容
临床试验/NCT04170686
NCT04170686已完成不适用

Acceptability and Efficacy of the Zemedy App for Irritable Bowel Syndrome

University of Pennsylvania2 个研究点 分布在 1 个国家目标入组 146 人开始时间: 2019年10月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
146
试验地点
2
主要终点
Irritable Bowel Syndrome Quality of Life

研究概览

简要总结

The purpose of this research is to assess if a new self-help app for IBS is an acceptable and effective intervention for improving the overall quality of life in patients with Irritable Bowel Syndrome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of IBS. Own a smart phone. Speak English

排除标准

  • Under age of consent (18) Diagnosed with another GI disorder (e.g. celiac disease, inflammatory bowel disease)

结局指标

主要结局

Irritable Bowel Syndrome Quality of Life

时间窗: 8 weeks

A self-report measure of health related quality of life (HRQL) in people with irritable bowel syndrome. Scores range from 0 to 100. Higher scores are a worse outcome.

Gastrointestinal Symptom Rating Scale

时间窗: 8 weeks

a self-report measure of GI symptom severity. Scores range from 0 to 78. Higher scores are a worse outcome.

次要结局

  • Visceral Sensitivity Index(8 weeks)
  • Fear of Food Questionnaire(8 weeks)
  • Depression Anxiety and Stress Scale - Anxiety Subscale(8 weeks)
  • GI Cognitions Questionnaire(8 weeks)
  • Patient Health Questionnaire(8 weeks)
  • Depression Anxiety and Stress Scale - Depression Subscale(8 weeks)
  • Depression Anxiety and Stress Scale - Stress Subscale(8 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Melissa Hunt, PhD

Associate Director of Clinical Training

University of Pennsylvania

研究点 (2)

Loading locations...

相似试验